{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:22:36Z","timestamp":1783488156819,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10637-017-0522-4","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T02:10:40Z","timestamp":1507687840000},"page":"350-353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer"],"prefix":"10.1007","volume":"36","author":[{"given":"Emi","family":"Date","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichi","family":"Fumita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7696-2391","authenticated-orcid":false,"given":"Hiroyasu","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"522_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5306\/wjco.v2.i3.150","volume":"2","author":"F Perri","year":"2011","unstructured":"Perri F, Lorenzo GD, Scarpati GD et al (2011) Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2:150\u2013157","journal-title":"World J Clin Oncol"},{"key":"522_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1758834009352667","volume":"2","author":"JA Sipos","year":"2010","unstructured":"Sipos JA, Shah MH (2010) Thyroid cancer: emerging role for targeted therapies. Ther Adv Med Oncol 2:3\u201316","journal-title":"Ther Adv Med Oncol"},{"key":"522_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2147\/OTT.S46545","volume":"9","author":"N Denaro","year":"2013","unstructured":"Denaro N, Nigro CL, Russi EG, Merlano MC (2013) The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther 9:1231\u20131241","journal-title":"Onco Targets Ther"},{"key":"522_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621\u2013630","journal-title":"N Engl J Med"},{"key":"522_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"M Tahara","year":"2017","unstructured":"Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Sasaki T, Suzuki T, Fujino K, Dutcus CE, Takahashi S (2017) Lenvatinib for Anaplastic Thyroid Cancer. Front Oncol 7:25","journal-title":"Front Oncol"},{"key":"522_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1677\/joe.0.1610041","volume":"161","author":"M Klein","year":"1999","unstructured":"Klein M, Picard E, Vignaud JM et al (1999) Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161:41\u201349","journal-title":"J Endocrinol"},{"key":"522_CR7","doi-asserted-by":"publisher","first-page":"638747","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K et al (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747","journal-title":"J Thyroid Res"},{"key":"522_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559\u2013568","journal-title":"Lancet Oncol"},{"key":"522_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.critrevonc.2013.10.002","volume":"89","author":"WX Qi","year":"2014","unstructured":"Qi WX, Sun YJ, Tang LN, Shen Z, Yao Y (2014) Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. (2014). Crit Rev Oncol Hematol 89:394\u2013403","journal-title":"Crit Rev Oncol Hematol"},{"key":"522_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350:2335\u20132342","journal-title":"New Engl J Med"},{"key":"522_CR11","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","volume":"20","author":"E Cutsem","year":"2009","unstructured":"Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842\u20131847","journal-title":"Ann Oncol"},{"key":"522_CR12","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1245\/s10434-006-9337-9","volume":"14","author":"MW Saif","year":"2007","unstructured":"Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860\u20131869","journal-title":"Ann Surg Oncol"},{"key":"522_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/annonc\/mdm508","volume":"19","author":"BD Badgwell","year":"2008","unstructured":"Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19:577\u2013582","journal-title":"Ann Oncol"},{"key":"522_CR14","first-page":"119","volume":"3","author":"AA Parikh","year":"2008","unstructured":"Parikh AA, Ellis LM (2008) Targeted therapies and surgical issues in gastrointestinal cancers. Targ. Oncologia 3:119\u2013125","journal-title":"Oncologia"},{"key":"522_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10456-010-9197-6","volume":"14","author":"M Walraven","year":"2011","unstructured":"Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM (2011) Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 14:135\u2013141","journal-title":"Angiogenesis"},{"key":"522_CR16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1177\/030089161109700618","volume":"97","author":"SG Park","year":"2011","unstructured":"Park SG, Chung CH, Park CY (2011) Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report. Tumori 97:794\u2013799","journal-title":"Tumori"},{"key":"522_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1477-7819-10-167","volume":"10","author":"T Inoue","year":"2012","unstructured":"Inoue T, Kinoshita H, Komai Y, Kawabata T, Kawa G, Uemura Y, Matsuda T (2012) Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J Surg Oncol 10:167","journal-title":"World J Surg Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0522-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0522-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0522-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:14:43Z","timestamp":1678511683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0522-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0522-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]},"assertion":[{"value":"13 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}